Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch (HES) Fluid Therapy
Key facts
- Who runs it
- Chiang Mai University
- Where
- Thailand1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 300 people enrolled
- Started
- 1 Mar 2025
- Ended
- 1 Mar 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- exposure to Hydroxyethyl Starch (HES) Voluven® or Volulyte® 130/0.4
- Record updated
- 17 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Inclusion CriteriaTo be included in the study, participants must meet all of the following requirements:Age: Patients must be at least 18 years old; Diagnosis: Patients must be diagnosed with a meningioma. Tumor Size: The tumor must be classified as "giant," defined as having a diameter of 5 cm or larger as seen on a CT scan; Surgery Type: Patients must have undergone a craniotomy to remove the tumor. Timeframe: The surgery must have occurred between the years 2016 and 2024
Who cannot take part
- Exclusion CriteriaPatients will be excluded from the study if they meet any of the following conditions:; Recurrent Cases: Patients with a recurrent meningioma (rather than a first-time surgery); Emergency Cases: Patients requiring an emergency craniotomy. Pregnancy: Any patient who is pregnant. Major Complications: Patients who experienced cardiac arrest during the surgery
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Project Summary: Retrospective Cohort Study
Read full original descriptionShow less
1. Core ObjectiveThe primary goal is to determine if the volume of Hydroxyethyl Starch (HES) 130/0.4 (specifically Voluven® or Volulyte®) administered during the removal of giant meningiomas (tumors > 5 cm) increases the risk of postoperative complications. 2. Research Question
Does the volume of intraoperative HES solution influence the rate of re-bleeding (requiring a second surgery within 48 hours) or the development of Acute Kidney Injury (AKI) within 7 days after the initial craniotomy?Outcomes: 3. Outcomes Primary: Incidence of re-bleeding at the tumor bed requiring re-operation within 48 hours Secondary: New-onset postoperative AKI within 7 days (defined by KDIGO criteria)
The 2 groups in the trial
- Exposed Group
Patients who received HES during surgery
Treatment: exposure to Hydroxyethyl Starch (HES) Voluven® or Volulyte® 130/0.4
- Non-Exposed Group
Patients who did not receive HES (received only crystalloids or other fluids).
Treatment: exposure to Hydroxyethyl Starch (HES) Voluven® or Volulyte® 130/0.4
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch (HES) Fluid Therapy: A Retrospective Cohort Study
- Record updated
- 17 March 2026